Identify Diagnostics

Identify Diagnostics Fentanyl Drug Test Cassette FEN FYL - CLIA WAIVED

(No reviews yet) Write a Review
This product is on a Pre-Order Status.
Calculated at Checkout
On Sale

Expected release date is 18th Apr 2024

Now: $45.00
Was: $55.00
Frequently bought together:


Identify Diagnostics FEN Fentanyl Drug Test Cassette  - BOXES OF 25 TESTS - CLIA Waived

The current expiration date for this drug test cassette is on or better than: MAY 31, 2025

This product is on a Pre-Order Status. Starts shipping 4/18/2024!

- CLIA Waived Fentanyl Test
- FDA Cleared 510K for OTC Over The Counter
- Purchase in bulk or small quantities to meet your specific volume needs

- Join our flexible auto-ship program to help make reordering easy
- For larger volume pricing please call 

Drugs Tested:
FEN - Fentanyl 1 ng/ml

This single panel drug test cassette is a lateral flow chromatographic Immunoassay for the qualitative detection of fentanyl metabolites in human urine.  

For the Identify Diagnostics drug test package CLIA Waived insert please click the icon below:

Identify Diagnostics, a renowned pioneer in the field of diagnostic testing, is proud to introduce its groundbreaking product: the Fentanyl Drug Urine Test Cassette. This innovative solution, with its CLIA Waived designation and FDA 510(k) clearance, sets a new standard for accessibility and convenience in drug testing. With results available in just 5 minutes after applying just three drops of urine, this OTC (Over-The-Counter) test cassette offers an unprecedented level of rapid and reliable Fentanyl detection.

Key features of the Identify Diagnostics Fentanyl Drug Urine Test Cassette:

CLIA Waived Designation: The Clinical Laboratory Improvement Amendments (CLIA) Waived designation ensures that this test can be safely and accurately performed outside of traditional clinical laboratory settings. This means that healthcare professionals and individuals alike can use it with confidence.

FDA 510(k) Clearance: The FDA 510(k) clearance is a testament to the product's rigorous testing and adherence to the highest standards of safety and accuracy set by the U.S. Food and Drug Administration.

Rapid Results: One of the standout features of this test cassette is its exceptional speed. In just 5 minutes, users can obtain clear and accurate results, which is particularly beneficial for those who need quick answers, such as healthcare professionals in emergency situations.

Minimal Urine Sample Required: Only three drops of urine are needed to perform the test. This minimal sample requirement makes it convenient for individuals and reduces discomfort or inconvenience during the testing process.

High Sensitivity and Specificity: The Fentanyl Drug Urine Test Cassette is designed to detect even trace amounts of Fentanyl in urine samples at just 1 ng/mL, ensuring that it can accurately identify potential exposure.

User-Friendly: The test cassette is designed with simplicity in mind. It comes with clear and easy-to-follow instructions, making it accessible to both professionals and individuals with minimal training.

Discreet and Private: This test offers a discreet and private solution for those who want to check for Fentanyl use or exposure without the need for healthcare professionals or laboratories.

Enhanced Safety: By providing quick results, this test contributes to enhanced safety in various settings, including emergency rooms, addiction treatment centers, and harm reduction programs.

The Identify Diagnostics Fentanyl Drug Urine Test Cassette is a game-changer in the field of drug testing. Its CLIA Waived status and FDA 510(k) clearance guarantee its accuracy and reliability. With rapid results available in just 5 minutes after a minimal urine sample is applied, it represents a valuable tool for healthcare professionals and individuals seeking to detect Fentanyl use or potential exposure swiftly and with confidence. This innovative product is poised to make a positive impact on healthcare, public safety, and harm reduction efforts in the ongoing fight against the opioid crisis. 



View AllClose

Additional Information

View AllClose